Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2013-07-25 | Dr. Goldstein received a B.S. from Stanford University, an M.B.A. from Columbia Business School and received his M.D. from Yale School of Medicine. We believe that Dr. Goldstein’s medical training and his experience in the biopharmaceutical industry as a venture capital investor, as an executive of Vicuron and a member of the boards of directors of other biopharmaceutical companies give him the qualifications and skills to serve as a director. |
| 2014-04-29 | Dr. Goldstein received a B.S. from Stanford University, an M.B.A. from Columbia Business School and an M.D. from Yale School of Medicine. ADMA believes that Dr. Goldstein’s medical training, his experience in the biopharmaceutical industry as a venture capital investor, as an executive of Vicuron and a member of the boards of directors of other biopharmaceutical companies, as well as his valuable perspective on ADMA’s business, give him the qualifications and skills to serve as a director. |
| 2015-04-30 | Dr. Goldstein received a B.S. from Stanford University, an M.B.A. from Columbia Business School and an M.D. from Yale School of Medicine. |
| 2016-04-29 | Dr. Goldstein received a B.S. from Stanford University, an M.B.A. from Columbia Business School and an M.D. from Yale School of Medicine. |
| 2018-04-27 | Dr. Goldstein received a B.S. from Stanford University, an M.B.A. from Columbia Business School and an M.D. from Yale School of Medicine. ADMA believes that Dr. Goldstein’s medical training and his experience in the biopharmaceutical industry as a venture capital investor, as an executive of Vicuron and a member of the boards of directors of other biopharmaceutical companies, as well as his valuable perspective on ADMA's business, give him the qualifications and skills to serve as a director. |
| 2019-04-24 | Dr. Goldstein received a B.S. from Stanford University, an M.B.A. from Columbia Business School and an M.D. from Yale School of Medicine. |
| 2019-07-16 | Dr. Goldstein is listed as a director with no indication of software or technical background. |
| 2020-04-29 | Dr. Goldstein received a B.S. from Stanford University, an M.B.A. from Columbia Business School and an M.D. from Yale School of Medicine. |
| Filing Date | Source Excerpt |
|---|---|
| 2014-04-04 | "From 2000 to 2005, Dr. Goldstein was Chief Financial Officer of Vicuron Pharmaceuticals, Inc.... He holds a B.S. in biology from Stanford University, an M.D. from the Yale School of Medicine and an M.B.A. from the Columbia Business School." |
| 2015-04-01 | "Dr. Goldstein is a Partner at Aisling Capital... He holds a B.S. in biology... an M.D.... and an M.B.A." |
| 2016-04-28 | "Dr. Goldstein is a Managing Partner at Aisling Capital... He holds a B.S. in biology... an M.D.... and an M.B.A." |
| 2017-03-06 | "Dov A. Goldstein, M.D., 49, has served as a member of our Board since April 2008... He holds a B.S. in biology from Stanford University, an M.D. from the Yale School of Medicine and an M.B.A. from the Columbia Business School." |
| 2018-04-13 | "Dr. Goldstein is currently the Chief Financial Officer... He holds a B.S. in biology ... an M.D.... and an M.B.A." |
| 2019-04-18 | "Dov A. Goldstein, M.D., 51... was a Managing Partner at Aisling Capital... He holds a B.S. in biology from Stanford University, an M.D. from the Yale School of Medicine and an M.B.A. from the Columbia Business School." |
| 2020-04-16 | "Dr. Goldstein and Dr. Newton's term as directors concluded on May 29, 2019." |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-05-04